User:Mr. Ibrahem/Infliximab
From Wikipedia, the free encyclopedia
Infliximab, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases including Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease.[2] It may be used together with methotrexate.[3] It is given by slow injection into a vein over at least 2 hours, with doses at six- to eight-week intervals.[2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | TNF |
Clinical data | |
Trade names | Remicade, Remsima, Inflectra, others |
Other names | Infliximab-abda, infliximab-axxq, infliximab-dyyb, infliximab-qbtx |
AHFS/Drugs.com | Monograph |
License data |
|
Pregnancy category |
|
Routes of administration | Intravenous (IV) |
Drug class | DMARD (biologic type)[2] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 92% (IV, if 8% left in the syringe) |
Metabolism | reticuloendothelial system |
Elimination half-life | 9.5 days |
Chemical and physical data | |
Formula | C6428H9912N1694O1987S46 |
Molar mass | 144190.64 g·mol−1 |
NY (what is this?) (verify) |
Common side effects include infections, acute infusion reactions, liver problems, and abdominal pain.[2] Other side effects may include cancer, reactivation of hepatitis B, worsening heart failure, and a lupus like condition.[2] It is unclear if use during pregnancy is safe.[4] Use during breastfeeding is likely safe for the baby.[3] Infliximab is a chimeric monoclonal antibody and biologic agent.[2] It seems to work by binding to and neutralizing TNF-α, preventing it from interacting with its receptors on the cell.[2]
Infliximab was approved for medical use in the United States in 1998,[2] and the European Union in August 1999.[5] It is on the World Health Organization's List of Essential Medicines as an alternative to adalimumab.[6] Biosimilars were approved in the EU in 2013,[7] Japan in 2014,[8] and the United States in 2016.[9] In the United Kingdom it costs about 377 pounds per 100 mg as of 2020.[3] In the United States this amount costs about 500 USD as of 2020 for a biosimilar.[10] In Canada the biosimilar is nearly half the price.[11]